Related Experiment Videos
Novel inhibitors of advanced glycation endproducts (part II)
S Rahbar1, K K Yerneni, S Scott
1Department of Diabetes, City of Hope National Medical Center, Duarte, California, 91010, USA. srahbar@coh.org
Abstract:
Enhanced formation and accumulation of advanced glycation endproducts (AGEs), have been implicated as a major pathogenesis process leading to diabetic complications, normal aging, atherosclerosis, and Alzheimer's Disease. Several potential drug candidates as AGE inhibitors have been reported recently. The aim of this study was to develop classes of novel inhibitors of glycation, AGE formation, and AGE-crosslinking and to investigate their effects through in vitro chemical and immunochemical assays. A total of 92 compounds were designed and synthesized. The first 63 compounds were reported before. Nearly half of the 29 novel inhibitors reported here are benzoic acid derivatives and related molecules, and found to be potent inhibitors of multistage glycation, AGE formation, and AGE-protein crosslinking. All 29 compounds show some degrees of inhibitory activities as detected by the four assay methods, 9 compounds demonstrated high percent inhibition (PI) in all tests, 30 to 40 times stronger than aminoguanidine.
Insights
Novel benzoic acid derivatives were synthesized and found to be potent inhibitors of advanced glycation endproduct (AGE) formation and crosslinking. These compounds show significant potential for treating AGE-related diseases like diabetes and Alzheimer's.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Pathology
Background:
- Advanced glycation endproducts (AGEs) are implicated in diabetic complications, aging, atherosclerosis, and Alzheimer's Disease.
- Inhibiting AGE formation and crosslinking is a therapeutic strategy for AGE-related pathologies.
- Previous research has identified potential AGE inhibitors, necessitating further development of novel compounds.
Purpose of the Study:
- To design and synthesize novel inhibitors of glycation, AGE formation, and AGE-protein crosslinking.
- To evaluate the in vitro inhibitory activities of these novel compounds.
- To identify potent AGE inhibitors for potential therapeutic applications.
Main Methods:
- Synthesis of 29 novel chemical compounds, primarily benzoic acid derivatives.
- In vitro evaluation using chemical and immunochemical assays to assess inhibitory activity.
- Comparison of inhibitory potency against a known inhibitor, aminoguanidine.
Main Results:
- All 29 novel compounds exhibited inhibitory activity against glycation and AGE formation.
- Nine compounds demonstrated high percent inhibition across all tested assays.
- Several benzoic acid derivatives showed potent inhibition, up to 30-40 times stronger than aminoguanidine.
Conclusions:
- Novel benzoic acid derivatives are effective inhibitors of multistage glycation, AGE formation, and AGE-protein crosslinking.
- These compounds represent promising therapeutic candidates for conditions associated with AGE accumulation.
- Further investigation into these potent AGE inhibitors is warranted.